New combo aims to boost CAR-T cell staying power in lymphoma
NCT ID NCT07489989
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding chidamide and a PD-1 inhibitor after CAR-T cell therapy can help prevent relapse in people with relapsed or refractory diffuse large B-cell lymphoma. The study plans to enroll 30 participants. The goal is to see if this maintenance strategy improves how long patients stay cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chidamide and a PD-1 inhibitor (drug combination)
What this could lead to
If successful, this combination could reduce relapse rates and improve long-term survival for people with hard-to-treat B-cell lymphoma.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The added drugs also carry risks of side effects like immune overactivation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China